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Abstract: Aptamers are artificial nucleic acid ligands identified and obtained from combinatorial
libraries of synthetic nucleic acids through the in vitro process SELEX (systematic evolution of ligands
by exponential enrichment). Aptamers are able to bind an ample range of non-nucleic acid targets
with great specificity and affinity. Devices based on aptamers as bio-recognition elements open up a
new generation of biosensors called aptasensors. This review focuses on some recent achievements
in the design of advanced label-free optical aptasensors using porous silicon (PSi) as a transducer
surface for the detection of pathogenic microorganisms and diagnostic molecules with high sensitivity,
reliability and low limit of detection (LoD).
Keywords: aptasensor; porous silicon; surface modification; aptamer; optical label free-sensing
1. Introduction
Biosensors are analytical hybrid devices comprising a bio-receptor (also called bioprobe)
immobilized on a transducer surface which is able to selectively recognize a molecular target [1,2].
The most commonly employed bioprobes in biosensors development are enzymes, proteins, and
antibodies (Abs), which suffer from various drawbacks, thus limiting their specific applications [3,4].
The enzyme isolation procedure and consequent incorporation in in vitro operating environments
could result in a loss of their activity [5]. The Abs are produced by the immune system in response to
exposure to antigens, i.e., spores, bacterial toxins, and other foreign substrates. Since Abs are difficult
to graft with a proper orientation, i.e., keeping their natural tridimensional structure, sometimes
they are less effective in antigen recognition [6]. Nowadays, new biomolecular recognition elements
which are able to overcome the Ab and enzyme constraints associated with standard bioprobes are in
growing demand in molecular sensing. In this context, aptamers are considered as to have the greatest
potential among the recognition tools which have developed in recent years. Aptamers are a class of
single-stranded RNA or DNA oligonucleotides which are able to fold into specific three-dimensional
(3D) structures, generated using the Systematic Evolution of Ligands by EXponential Enrichment
(SELEX) technique [7]. This process, relying on DNA or RNA libraries, is able to automatically
synthesize a large variety of nucleic acid sequences with great selectivity for non-nucleic acid molecules.
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Aptamers are able to interact with their targets through structural recognition similar to that of the
antibody-antigen reaction with a dissociation constant in the range of pico- to nano-molar. For these
reasons, aptamers are usually referred as chemical Abs [8]. Moreover, an appealing characteristic
of aptamers, as opposed to Abs, is their efficacy against small molecules where antibodies fail [9].
Different from Abs, the chemical nature of nucleic acids makes them easy to synthesize and engineer,
and thereby, to obtain aptamers with extended bioavailability, regulating ability, and multi-functional
properties [10,11]. Aptamers are thermally stable; even after denaturation temperature, they are able to
refold into their 3D formations once at room temperature, in contrast to protein-based Abs, which totally
lose their activity at high temperatures. The targets of aptamers range from small molecules to proteins,
virus-infected cells, stem cells, and cancer cells. The chemical properties and biological activity of
aptamers have made them attractive for use in biomedical applications ranging from bioassays to
targeted therapy [12]. Moreover, aptamer technology has shown great potential for bioengineering
of nanostructured devices. Aptamers used as bioprobes for the development of biosensors have
heralded a new generation of biosensors called aptasensors [13]. A variety of aptasensors have been
developed based on fluorescence, electrochemiluminescence, surface plasmon resonance (SPR) and
surface-enhanced Raman scattering (SERS) [14–16]. Label-free optical aptasensors can be designed
using porous silicon (PSi)-based devices. PSi is a nanostructured material which is widely used as
a transducer surface in biosensing. Its sponge-like morphology, characterized by a specific surface
area of about 500 m2 cm−3, ensures active and rapid interaction with the species to be detected [17].
Additional advantages of PSi are compatibility with semiconductor processing and largely tunable
pore size (nanometers to microns), which makes possible the infiltration of appropriate-sized target
molecules while excluding larger-sized, non-specific ones [18]. The result of PSi optical transducer
response to binding of inorganic/organic matter on pore walls is a change of its average refractive
index [19]. A PSi layer acts optically as a Fabry-Perot interferometer: the substitution of air in the
pores enhances the average refractive index, resulting in a change in the reflectivity spectrum [20].
The analysis of the optical spectra by fast Fourier transform (FFT) could be used as a simple method to
assess variations in the refractive index [21]. This review presents recent progress in the development of
label-free PSi optical aptasensors for biomedical applications. Different PSi functionalization strategies
for the development of such devices for the detection of molecules of diagnostic interest (i.e., insulin,
bacteria, human thrombin) are described. In particular, the improvement of device performance in
terms of sensitivity, response time and limit of detection (LoD) will be discussed.
2. Porous Silicon Optical Devices for Label-Free Biosensing
Over the past two decades, great interest has shown by many researchers in the improvement of
label-free biosensors. Most standard biosensors need a label attached to the target, and their detection
and quantification is assumed to correspond to the number of bound targets [22]. Labels are easily
detectable entities, such as fluorophores, magnetic beads, active enzymes. However, the labeling
procedure requires sample handling that can drastically change its biomolecule binding properties,
as well as the target-label coupling reaction yield. In label-free biosensors, no label is required for
the sensing. This technology is based on the direct measurement of a signal (optical, electrical or
mechanical) which is generated by the interaction between the bioprobe and the analyte on the
transducer surface [23–25]. Sensitive, fast, robust, low cost, label-free biosensors are highly desirable
for a broad range of applications including medical disease monitoring, controlled release of drugs,
and food security [26–28]. PSi has received remarkable interest as a transducer surface for the
construction of low-cost, sensitive and biocompatible optical label-free biosensors [2]. This is mainly
due to its intriguing physicochemical properties which makes possible the design of compact biosensors
with high performance [29]. Moreover, PSi transducers can be optimized (pore size, pore depth,
and porosity) to suit specific applications by controlling the etching parameters [30,31]. Label-free PSi
optical biosensors, using interferometric reflectance spectroscopy (IRS), have demonstrated outstanding
performance in terms of the rapid and reliable detection of several analytes [32]. IRS technique is
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based on a very simple set up: an incident white light is reflected on the two interfaces (air-PSi and
PSi-bulk Si) of the porous material, producing a Fabry-Perot interference fringe pattern, depending on
the optical thickness (physical thickness L times the refractive index (n) of the porous material) [33,34].
The fringe pattern is described by Equation (1);
mλ = 2 nL (1)
where λ is the maximum wavelength of two consecutive fringes with an order of magnitude m, L is
the thickness of the porous layer and 2 nL is the effective optical thickness (EOT). The EOT can be
determined by applying FFT to the observed interference fringe pattern; this parameter is usually
used to measure the sensor response. When an analyte is captured by the bioprobe-modified PSi,
a redshift of the fringe pattern is observed. This phenomenon is due to the substitution of air within
the pores with the analyte—which has a higher refractive index—resulting in an increase in the EOT
value [35]. Thus, the interferometric reflectance spectroscopy enables the simple detection of analytes
by monitoring changes of EOT over time.
Porous Silicon Fabrication and Surface Modification Strategies
The peculiar morphological, physical, and chemical properties of PSi make it one of the most
explored nanostructured materials, as evidenced by the great number of papers about its features,
and the prevalence of devices based on this material [36–40]. One reason for its success is the
easy fabrication process based on a computer-controlled electrochemical etching procedure and
a simple power supply. The PSi structure is obtained by electrochemical dissolution of doped
crystalline silicon wafers in a hydrofluoric acid (HF) -based solution. Modulating parameters such
as current density, type and concentration of crystalline silicon dopant, and the composition of
electrolyte solution makes it possible to obtain porous structures with specific morphological and
optical properties [31,39]. The silicon hydride (Si–H) terminated pore walls of as-etched PSi are
prone to oxidation and dissolution under ambient conditions, such as atmospheric oxygen, water,
and aqueous solutions [41]. The oxidation of PSi causes a significant change in the refractive index
of the material (n = 3.5 for silicon, n = 1.4 for silicon dioxide), interfering with transduction signal
of PSi optical biosensors. Moreover, dissolution in aqueous buffers leads to even greater changes
in the refractive index (n = 3.5 for silicon, n = 1.33 for water), with a loss of signal due to PSi
structural collapse [42]. The PSi surface should be properly stabilized for biosensing applications.
A common method to prevent PSi from degradation is to intentionally grow an oxide layer on the
surface via thermal oxidation, which reduces or completely removes the Si–H from the entire skeleton,
substituting it for SiO2, which isotropically grows also in the pores [43]. To provide greater stability
and protection against dissolution, the oxidized surface could be chemically modified with alkyl
silanes. The two most popular silane coupling agents are 3-aminopropyl-triethoxysilane (APTES) and
3-aminopropyl-dimethyl-ethoxysilane (APDMES), both of which are able to form a dense monolayer
on the PSi surface through Si–O–Si covalent bonds that limit the access of water to the underlying
surface [44]. The hydrosilylation is an alternative surface-chemistry process involving the grafting of
alkenes (or alkynes) to the hydride-terminated PSi surface, resulting in the formation of a monolayer of
alkyl chains which is covalently attached to the surface through Si-C, showing much greater resistance to
attack by nucleophiles such as water or hydroxide [41,45,46]. This reacting mechanism can be promoted
by heat, light, Lewis acid catalysts in an inert atmosphere and completely deoxygenated/dried reagents,
thus avoiding the formation of silicon oxides during the monolayer formation [47]. The grafting of
alkyl silanes and alkanes/alkynes on PSi makes the surface chemically stable in aqueous solution,
thereby avoiding surface oxidation or chemical degradation. Moreover, these passivation methods are
valid strategies to functionalize the surface with reactive groups (−NH2, −COOH, −SH, and −CHO)
for the subsequent conjugation of biomolecules (i.e., enzymes, proteins, Abs, peptides, DNA, aptamer).
Additional methods used for PSi surface stabilization can be found in ref. [48]. From a sensing point of
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view, passivation/functionalization methods avoid the zero-point drift without altering the intrinsic
sensitivity of the devices.
PSi biosensors are usually prepared by immobilizing the bioprobe on the transducer surface,
once it has been synthesized by an ex situ procedure. However, there is also an innovative procedure
for the preparation of biosensors based on the direct growth of the bioprobe (i.e., by in situ synthesis)
on PSi used as support in so-called solid phase synthesis [49,50].
3. Label-Free Porous Silicon Apatasensor for Human Diseases Diagnosis
Aptamers are an emerging class of single-stranded oligonucleotides which is generated using
SELEX technology [8,51]. By folding them into well-defined secondary or tertiary structures,
aptamers are able to specifically bind their target molecules with high affinity, and so are classified as
powerful ligands for diagnostic and therapeutic applications [52]. They present significant advantages
over conventional bioprobes (e.g., Abs), such as relatively low-molecular-weight and high stability,
great affinity due to the remarkable low dissociation constants (Kd) aptamer/target ranging from
picomolar to nanomolar levels, and great selectivity thanks to their ability to recognize even minor
structural differences between targets and their analogs. To date, aptamer-based biosensors have been
successfully used for the detection of a large number of analytes of interest due to the highly selective
interactions between the aptamer and the target, and the high amplification thanks to the optical,
electrical or magnetic properties of the various sensing platforms. These novel integrations highlight
the potential of aptamers as emerging tools for the fabrication of new sensing devices for the selective
and sensitive detection of a wide range of targets, promising great advances in healthcare applications.
3.1. Aptamer-Decorated Porous Silicon Biosensor for Rapid Detection of Bacteria
Rapid detection and identification of bacterial contaminations in blood are a major challenge in
today’s medical practice [53]. A bacterial contamination can occur in every environment, causing
a specific disease in a variety of ways; even today, microbial diseases are a major cause of death
in many countries [54]. The detection and identification of bacterial contaminations is still based
on traditional microbiological techniques, which typically require several days to obtain results,
making ‘real-time’ assessments unfeasible. Over the past decade, great efforts have been directed
toward the development of new bioassays and biosensors for the rapid detection of pathogenic
bacteria [55]. Various biosensors for fast bacteria detection have been reported; among them, the
most popular are optical biosensors. These biosensors offer several advantages, including selectivity,
speed, sensitivity, and reproducibility of measurements. Recently, Prof. E. Segal and co-workers at
Technion, Haifa, Israel [56], described the design of an optical aptamer-based PSi biosensor for the direct
capture of Lactobacillus acidophilus, employing the Hemag1P aptamer as a capture probe. The Hemag1P
aptamer is 78-nucleotide-long sequence selected by the SELEX technique against the L. acidophilus
membrane, i.e., a strain of bacteria which is important for the functional food and pharmaceutical
industry. This aptamer is able to target the S-proteins which are abundantly present on the bacteria
membrane. The first step in the Hemag1P-PSi aptasensor preparation was the anodization process of a
Si wafer (300 mA cm−2, 30 s) and its thermal oxidation, thus obtaining oxidized PSi (PSiO2). The PSiO2
is decorated with the aptamer through the three-step biofunctionalization route, as illustrated in
Figure 1. The PSiO2 is first silanized with 3-mercaptopropyl-trimethoxysilane (MPTMS) and then
reacted with acrydite-modified Hemag1P aptamer via a thioether bond. The final functionalization step
is the blocking of residual thiol groups of the aptamer with maleimide, in order to reduce non-specific
reactions with the buffers. The success of aptamer immobilization on the PSi surface was confirmed
using attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy and Ellman
colorimetric assay for thiol-groups. The biosensing mechanism of the Hemag1P-aptasensor was based
on monitoring changes in the intensity of fast Fourier transformation (FFT) peaks, obtained from the
raw PSi reflectivity spectra during exposure to bacteria suspensions. The Hemag1P-modified PSiO2
biosensor was exposed to L. acidophilus suspensions while the reflectivity spectra changes of the device
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were monitored in real time (Figure 2). Firstly, the initial intensity baseline was established by exposing
the aptasensor to the aptamer selection buffer solution (SB). Then, the biosensor was incubated with the
bacteria solution (107 cells per mL in SB) for 20 min, allowing bacteria/aptasensor interactions to occur.
Consequent washing of the biosensor with SB was performed to remove unbound bacteria, after which
the intensity increased and stabilized at a net intensity decrease value of 5.5%. Several replications of
this biosensing experiment have demonstrated similar behavior to that represented in Figure 2, and a
highly reproducible net intensity decrease value of 5.5% (0.07%), confirming the ability of the biosensor
to detect 106 cells per mL of L. acidophilus.
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experiment depicts L. acidophilus cells captured onto the aptamer-modified PSiO2 device. Reproduced
with permission from [56].
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Staphylococcus aureus is a major cause of bacteremia and infections in humans, as well as food-borne
diseases [57]. S. aureus treatment is especially challenging due to the bacteria’s ability to rapidly
adapt and develop resistance to antibiotics; thus, a fast and reliable means of detection of such
bacteria is crucial for the effective control of infection. Protein A (PA, 45 kDa), secreted by and
displayed on the cell membrane of S. aureus, is considered a significant biomarker for this bacteria.
K. Urman et al. [58] developed a label-free optical PSi aptasensor for the specific detection of PA.
Protein A-targeting aptamers (PAA) are conjugated to APTES-modified PSiO2 thin films by standard
carbodiimide-coupling chemistry [59,60]. PSiO2 surface modification and aptamer-conjugation were
confirmed by ATR-FTIR analyses. The PAA-PSiO2 biosensor was exposed to PA solutions at different
concentrations, and the biosensor response, evaluated as effective optical thickness (EOT) changes,
showed a relative EOT increment with increasing PA concentration. The results demonstrated a
specific detection and quantification of PA in a range of 2–50 µM, with a binding affinity towards PA of
13.98 µM and LoD of 3.17 µM. Due to the affinity between PA and the antibody, IgG was introduced
in a sandwich-assay format to enhance the sensitivity of the biosensor by three fold. In Figure 3,
the exposure of a PAA-biosensor to either PA or IgG (as control) gave insignificant signals, i.e., below the
critical value (3 × σ = 0.205) calculated for the LoD. The values obtained by the sandwich assay were
six times higher (1.2 ± 0.3 as ∆EOT/EOT0 × 103), resulting in a PA LoD value of 1 µM. This work
demonstrated a proof-of-concept scheme for increasing three-fold the sensitivity of PAA-functionalized
PSi biosensors by taking advantage of PA and IgG affinity.
Molecule  2019, 24, x  6 of 13 
 
bacteria is crucial for the effective control of infection. Protein  (P , 45 kDa), secreted by and 
displayed on the cell e brane of S. aureus, is considered a significant bio arker for this bacteria. 
K. Ur an et al. [58] developed a label-free optical PSi aptasensor for the specific detection of P . 
Protein A-targeting aptamers (PAA) are conjugated to APTES-modified PSiO2 thin fil s by standard 
carbodiimide-coupling chemistry [59,60]. PSiO2 surface odification and apta er-conjugation ere 
confirmed by ATR-FTIR analyses. The PAA-PSiO2 biosensor as exposed to P  solutions at different 
concentrations, and the biosensor response, evaluated as effective optical thickness (E T) changes, 
sho ed a relative EOT increment with increasing PA concentration. The results demonstrated a 
specific detection and quantification of PA in a range of 2–50 μM, with a binding affinity towards PA 
of 13.98 μM and LoD of 3.17 μM. Due to the affinity between PA and the antibody, IgG was 
introduced in a sandwich-assay format to enhance the sensitivity of the biosensor by three fold. In 
Figure 3, the exposure of a PAA-biosensor to either PA or IgG (as control) gave insignificant signals, 
i.e., below the critical value (3 × σ = 0.205) calculated for the LoD. The values obtained by the sandwich 
assay were six times higher (1.2 ± 0.3 as ΔEOT/EOT0 × 103), resulting in a PA LoD value of 1 μM. This 
work demonstrated a proof-of-concept scheme for increasing three-fold the sensitivity of PAA-
functionalized PSi biosensors by taking advantage of PA and IgG affinity. 
 
Figure 3. Sensitivity enhancement of the PAA-functionalized PSiO2biosensor. Averaged optical 
response (relative EOT) of the biosensor upon exposure to 1 M of: PA, IgG or both in a successive 
manner. Schematic illustration of biomolecules captured by the aptamers within the porous scaffold. 
Upper dashed line indicates the LoD value. Differences between both single exposures (of PA or IgG) 
and the sandwich assay are statistically significant (p < 0.05, n ≥ 3). Reproduced with permission from 
[58]. 
3.2. Porous Silicon Aptasensor for Detection of Insulin  
Diabetes mellitus is a worldwide health problem, and severe complications associated with this 
disease are causes of death [61]. Diabetes mellitus is a pathological state resulting from an absolute 
or relative deficiency of insulin in the body. Insulin is a hormone synthesized by the β cells of the 
pancreatic Islets of Langerhans. The carrier glucose transporter (type 4) is able to bind with insulin, 
allowing glucose entry to the heart, muscles, and brain cells. When the regulatory mechanisms fail, a 
hyperglycemia occurs; blood glucose concentrations increase to over 7.0 millimoles per liter, and 
random glucose concentrations increase to over 11.1 millimoles per liter [62]. Long-term 
hyperglycemia may be the cause of several life-threatening complications such as cardiovascular 
diseases, diabetic nephropathy, neuropathy, and retinopathy. The monitoring of glucose blood levels 
Figure 3. Sensitivity enhancement of the PAA-functionalized PSiO2 biosensor. Averaged optical
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manner. Schematic illustration of biomolecules captured by the aptamers within the porous scaffold.
Upper dashed line indicates the LoD value. Differences between both single exposures (of PA or IgG)
and the sandwich assay are statistically significant (p < 0.05, n ≥ 3). Reproduced with permission
from [58].
3.2. Porous Silicon Aptasensor for Detection of Insulin
Diabetes mellitus is a worldwide health problem, and severe complications associated with
this disease are causes of death [61]. Diabetes mellitus is a pathological state resulting from an
absolute or relative deficiency of insulin in the body. Insulin is a hormone synthesized by the β
cells of the pancreatic Islets of Langerhans. The carrier glucose transporter (type 4) is able to bind
with insulin, allowing glucose entry to the heart, muscles, and brain cells. When the regulatory
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mechanisms fail, a hyperglycemia occurs; blood glucose concentrations increase to over 7.0 millimoles
per liter, and random glucose concentrations increase to over 11.1 millimoles per liter [62]. Long-term
hyperglycemia may be the cause of several life-threatening complications such as cardiovascular
diseases, diabetic nephropathy, neuropathy, and retinopathy. The monitoring of glucose blood
levels is the first step in diagnoses of diabetes mellitus, whereby a rapid and accurate diagnosis
method is necessary for the prevention of lethal complications. Standard diagnostic techniques
(e.g., enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), chromatography) are
typically laborious, expensive, time-consuming and require sophisticated laboratory equipment.
Recently, Prof. N.H. Voelker and co-workers at Monash Institute, Melbourne, Australia [63],
developed two different label-free PSi-based optical biosensors for the detection of insulin secreted
by human pancreatic islets: an antibody-modified PSi (Ab-modified) and an aptamer-modified PSi
(Ap-modified). Freshly etched PSi single layer structures were exposed to a thermal hydrosilylation
reaction with undecylenic acid, followed by reaction with carbodiimide chemistry (EDC/NHS),
the immobilization of the Ab (150 kDa) or the aptamer (9.7 kDa) and, finally, (d) quenching of
active NHS ester with bis-PEG-amine (BPA). Both of the prepared PSi devices (i.e., Ab-modified-
and Ap-modified-PSi) were tested as optical biosensors for the detection of insulin under the same
conditions in a Krebs Ringer buffer (a solution used for glucose-stimulated insulin secretion clinical
assay). The devices were exposed to Krebs buffer for 20 min to establish a baseline, and no significant
change in ∆EOT value was observed. The exposure of the PSi devices to insulin (50 µg/mL) solution for
60 min increased ∆EOT, and finally, rinsing with Krebs buffer for 20 min was carried out. The results
showed that Ap-modified PSi outperformed Ab-modified PSi devices in terms of insulin detection time
and sensitivity: 19 nm EOT shift in 12 min compared to 16 nm EOT shift in 60 min. The rapid response
of Ap-modified PSi is associated with the exclusive conformation change of the aptamer during insulin
binding, highlighting the potential benefit of using aptamers rather than Abs as bioprobes in biosensor
development. Ap-modified PSi was tested as a biosensor in a real sample detection of insulin secreted
by human donor islets. Human islets (40,000 IEQ) were stimulated with 20 mM glucose for 2 h in Krebs
buffer, after which the cells were centrifuged and the insulin-containing supernatant was used for the
sensing experiment, following the previously-described protocol. The exposure of the Ap-biosensor to
insulin (20 mM) in Krebs solution showed a gradual increase in ∆EOT with a maximum shift of ~17 nm
over 80 min (Figure 4). After the washing step with Krebs buffer, no significant change in ∆EOT was
observed. Applying the maximum ∆EOT shift to the calibration curve obtained for the Ap-modified
surface, a concentration of 15.4 µg/mL was obtained. In addition, no significant changes to ∆EOT were
observed on the control surface, except for a small blue shift as a result of a slight degradation of PSi in
the aqueous medium. For comparison, the ELISA technique was used to determine the level of insulin
in the real sample, showing a result of 16.9 ± 0.2 µg/mL, which is in agreement with the result of the
Ap-PSi biosensor. These results demonstrated, for the first time, the great capability of the Ap-modified
PSi surface to detect insulin secreted by human islets from a donor upon stimulation with glucose.
Recently, N.H. Voelker and co-workers [64] demonstrated the optimization of PSi fabrication for
the development of optical insulin biosensors with high sensing performance in terms of response
time and LoD. PSi rugate filter (PSiRF) were modified by thermal hydrosilylation and conjugated to an
insulin binding aptamer (IBA) at different concentrations (1, 10, 20, 50 and 70 µM) via carbodiimide
chemistry. The different prepared surfaces were tested for insulin detection (50 µg/mL) using IRS in
order to verify the effect of IBA concentration on biosensing device performance. Insulin biosensing
was carried out on each prepared PSi device with 20 min PBS baseline, 30 min 50 µg/mL insulin flow,
and 30 min PBS washing. Generally, a high bioprobe density is preferred in biosensor development in
order to guarantee the highest target binding capacity. In this specific case, the obtained result showed
the opposite trend, i.e., the surface obtained with a low aptamer concentration (1 µM) performed better
compared to the surface prepared using the highest aptamer concentration (70 µM) (Figure 5).
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This phenomenon might be due to a steric hindrance effect that could prevent the aptamer from
folding into the correct 3D conformation required to show the highest insulin affinity [64]. The optimized
PSi biosensor platform was then applied to detect insulin in a real sample. For biosensing experiments
with IRS, the sensor surface was exposed to Krebs buffer flow for 20 min, followed by supernatant
containing the insulin secreted by human islets (20000 IEQ), and then washed with Krebs buffer for
30 min. At first, a steady baseline was achieved in the Krebs buffer, and no shift in the peak wavelength
was observed. Then, the supernatant with secreted insulin was flowed over the biosensor surface and
a gradual red shift was observed, as a result of insulin/IBA binding. During the final washing step,
a decrease in the maximum wavelength was observed due to the removal of unbound insulin from the
biosensor surface. A shift of 0.19 nm calculated by subtracting the final wavelength value from the
initial baseline value was applied to the linear regression equation from the calibration curve (data not
shown) in Krebs buffer and the calculated concentration of insulin in the real sample was 1.3 µg/mL.
This result was confirmed by an ELISA test validating the PSiRF sensor as a successful device for the
detection of insulin secreted by human islets stimulated with glucose.
3.3. Macroporous Silica Aptasensor for Label-Free Optical Quantification of Human Thrombin
Human thrombin (MW ≈ 37 kDa) is a serine protease—also known as coagulation factor
II—which is able to convert soluble fibrinogen (factor I) into insoluble strands of fibrin (factor Ia),
with a fundamental role in coagulation and hemostasis. The balance between its production and
inhibition avoids hemorrhagic or thrombosis phenomena, which may be fatal to human health. In a
healthy subject, thrombin concentration is almost absent until it passes from from nM to µM levels
during the coagulation process [65]. Pathological coagulation disorders, such as ischemic stroke or
thromboembolism, could be induced by high levels of thrombin in the blood (beyond the normal
coagulation phenomenon) [66]. Moreover, the deregulation of neuronal PAR1-activation by thrombin
has been associated with many disorders of the central nervous system (SNC), including the Alzheimer
and Parkinson diseases, and the role of thrombin in cancer is well known [67,68]. The important role of
thrombin in different (patho)physiological processes has triggered interest in the possible discovery of
novel thrombin inhibitors, as well as in the development of new devices which are capable of rapidly
detecting its level in blood with high selectivity and very low LoD [69,70]. M. Terracciano et al. [71]
described the fabrication of a label-free PSi optical aptasensor by in situ synthesis of a 15-mer thrombin
binding aptamer (TBA) on silanized macro-PSi for the quantification of human α-thrombin levels.
The high sensitivity, selectivity, and reversibility of the obtained aptasensor were also demonstrated.
Macro-PSi structure (pores size > 50 nm), after thermal oxidation, was functionalized by grafting
aminosilane compound (APTES), and bioconjugated to a TBA probe by an in situ synthesis [72].
Figure 6 shows the reflectivity spectra (A) with the corresponding FFTs (B) of APTES-modified PSi
before and after the in situ synthesis process. The calculated FFT peak shift of 36 nm confirmed
the success the TBA growth on the PSi structure. This result was also confirmed by the coupling
yield analysis of the 5′-dimethoxytritil (DMT) group released into the solution after each synthesis
cycle using ultraviolet (UV) spectroscopy. The PSi surface functionalization with TBA (FTBA) was
quantified using the Lambert-Beer law (DMT molar absorptivity ε = 71,700 M−1 cm−1, λ = 500 nm)
and UV intensity value corresponding to the last synthesized nucleotide, i.e., IN17 = 0.055 ± 0.001.
The FTBA was calculated to be (1.92 ± 0.03) × 10–5 mol/g for PSi sample with a weight of 0.2 mg.
The PSi surface functionalization in terms of nmol cm–2 evaluated using the ratio FTBA/SSA (specific
surface area of PSi 199 m2 g−1 evaluated by the Brunauer–Emmett–Teller analysis) was found to be
0.0125 ± 0.0002 nmol cm–2. For biosensing experiments, the aptasenosr was exposed to different
thrombin concentrations (13, 27, 54 and 109 nM). The TBA-thrombin interaction was monitored using
spectroscopic reflectometry, demonstrating the technique’s ability to recognize the analyte at different
molar concentrations. The calculated affinity constant was 14 ± 8 nM, with a sensitivity of 4.1 ± 0.8 nm
nM−1 and LoD of 1.5 ± 0.3 nM. The LoD value was lower than other well-known, very sensitive
assays [73]. Moreover, the reversibility of the PSi-aptasensor was also proved. The PSi-aptasensor was
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regenerated by treatment in water at 53 ◦C, corresponding to the melting temperature of TBA [74].
At this temperature, TBA lost the typical G-quadruplex structure, as well as its affinity with thrombin.
However, this process was reversible: by exposing TBA-PSi to thrombin and/or monovalent cations
at room temperature, the aptamer folded again into a G-quadruplex structure [75]. The device
regeneration induced a decrease of optical thickness (about 14 nm) due to the release of thrombin from
the PSi pores. An increase of 38 nm was observed after exposing the device to 109 nM of thrombin
solution, thus proving the ability of the aptasensor to recognize the analyte. The results reported in
this work endorse macro–PSi as a suitable substrate for the realization of a wide range of aptasensors
using an in situ synthesis approach for surface functionalization.
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detection systems with tailored characteristics offers to the biosensing field the chance to explore new
and dynamic routes of biosensor development. The possibility of commercializing aptasensors in the
near future can therefore be reasonably foreseen.
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